JPRN-UMIN000028749CompletedPhase 2
A phase II study of perioperative capecitabine plus Oxaliplatin(CapeOx) therapy for advanced gastric cancer with multiple lymph node metastases (OGSG 1701) - A phase II study of perioperative capecitabine plus Oxaliplatin(CapeOx) therapy for advanced gastric cancer with multiple lymph node metastases (OGSG 1701)
Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)0 sites30 target enrollmentStarted: September 1, 2017Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 30
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 75years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1)With active double cancers excluding carcinoma in situ and/or prior cancer cured with longer than 5 year interval period 2)Pregnant or nursing female 3)Male expecting pregnancy of partner 4)Impossible to register to the study due to a psychological disorder by physician in charge's decision 5)Under continuous steroids medication 6)Patients who receives systemic continuous administration of phenytoin or warfarin potassium 7)With neuropathy on peripheral motor and/or sensory nerves: -> glade 2 of CTCAE v4.0 8)With interstitial pneumonitis, pulmonary fibrosis and/or severe pulmonary emphysema 9)With active bacterial/fungal infectious disease (with a fever over 38 centigrade) 10)With a history of cardiac infarction and/or anxiety angina pectoris within 6 months 11)With uncontrollable blood hypertension 12)With uncontrollable DM 13)With uncontrollable Diarrhea 14)Positive HBs antigen 15)Severe complications 16)Any other patients whom the physician in charge of the study judges to be unsuitable
Investigators
Similar Trials
Active, not recruiting
Phase 2
OGSG 1701advanced gastric cancer with lymph node metastases cannot be resected curatively, or poor prognosis.JPRN-jRCTs051180186SUGIMOTO Naotoshi30
Recruiting
Not Applicable
Phase I/II trial of preoperative capecitabine with concurrent radiation therapy for locally advanced rectal cancer in a Japanese population.rectal cancerJPRN-UMIN000003701Wakayama Medical University, Second Department of Surgery38
Not yet recruiting
Phase 2
Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative ChemotherapyHER2-positive Breast CancerNCT03684863Shandong Cancer Hospital and Institute200
Active, not recruiting
Phase 1
STUDY OF CAPECITABINE PLUS CONCOMITANT RADIATION THERAPY FOLLOWED BY DURVALUMAB AS PREOPERATIVE TREATMENT IN PATIENTS WITH RECTAL CANCERocally advanced (T3-4 N0-1) rectal cancer.MedDRA version: 21.0Level: PTClassification code 10038019Term: Rectal adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004758-39-ITAZIENDA UNITÀ SANITARIA LOCALE DELLA ROMAGNA60
Active, not recruiting
Not Applicable
A phase II study of Capecitabine in combination with Cisplatin in advanced head and neck Cancer - NDAdvanced or metastatic head and neck cancerLevel: HLTClassification code 10024530EUCTR2006-003775-13-ITOSPEDALE ONCOLOGICO DI BARI43